CoChat

Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial

Open access

The DOI matches its Crossref record; 55 of the 56 references it cites were found in a registry or an index, and 1 are not checked yet.

Abstract

Neoantigens, which are derived from tumour-specific protein-coding mutations, are exempt from central tolerance, can generate robust immune responses 1,2 and can function as bona fide antigens that facilitate tumour rejection 3. Here we demonstrate that a strategy that uses multi-epitope, personalized neoantigen vaccination, which has previously been tested in patients with high-risk melanoma 4-6, is feasible for tumours such as glioblastoma, which typically have a relatively low mutation load 1,7 and an immunologically 'cold' tumour microenvironment 8. We used personalized neoantigen-targeting vaccines to immunize patients newly diagnosed with glioblastoma following surgical resection and conventional radiotherapy in a phase I/Ib study. Patients who did not receive dexamethasone-a highly potent corticosteroid that is frequently prescribed to treat cerebral oedema in patients with glioblastoma-generated circulating polyfunctional neoantigen-specific CD4+ and CD8+ T cell responses that were enriched in a memory phenotype and showed an increase in the number of tumour-infiltrating T cells. Using single-cell T cell receptor analysis, we provide evidence that neoantigen-specific T cells from the peripheral blood can migrate into an intracranial glioblastoma tumour. Neoantigen-targeting vaccines thus have the potential to favourably alter the immune milieu of glioblastoma.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41586-018-0792-9

Cites

55 of 56 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 56 references

Cited by

See all 1,432

Metadata

Authors
Keskin, D. B., Anandappa, A. J., Sun, J., Tirosh, I., Mathewson, N. D., Li, S., Oliveira, G., Giobbie-Hurder, A., Felt, K., Gjini, E., Shukla, S. A., Hu, Z., Li, L., Le, P. M., Allesøe, R. L., Richman, A. R., Kowalczyk, M. S., Abdelrahman, S., Geduldig, J. E., Charbonneau, S., Pelton, K., Iorgulescu, J. B., Elagina, L., Zhang, W., Olive, O., McCluskey, C., Olsen, L. R., Stevens, J., Lane, W. J., Salazar, A. M., Daley, H., Wen, P. Y., Chiocca, E. A., Harden, M., Lennon, N. J., Gabriel, S., Getz, G., Lander, E. S., Regev, A., Ritz, J., Neuberg, D., Rodig, S. J., Ligon, K. L., Suvà, M. L., Wucherpfennig, K. W., Hacohen, N., Fritsch, E. F., Livak, K. J., Ott, P. A., Wu, C. J., & Reardon, D. A.
Affiliations
  • Broad Institute (US)
  • Harvard University (US)
  • Dana-Farber Cancer Institute (US)
  • Brigham and Women's Hospital (US)
  • Technical University of Denmark (DK)
Corresponding author
Reardon, David A.
Venue
Nature
Published
2018-12-19
Volume
565
Issue
7738
Pages
234-239
ISSN
  • 0028-0836 (ISSN-L)
  • 1476-4687
OpenAlex
W2904803926
Cited by
1,432
References
55
Citations by year
2026: 150 · 2025: 157 · 2024: 168 · 2023: 172 · 2022: 223 · 2021: 252 · 2020: 203 · 2019: 101 · 2018: 2
FWCI
52.97
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
  • Digital Access to Scholarship at Harvard (DASH) (Harvard University) (acceptedVersion)
  • DSpace@MIT (Massachusetts Institute of Technology) (submittedVersion, cc-by-nc-sa)
  • RePEc: Research Papers in Economics (submittedVersion)
  • Technical University of Denmark, DTU Orbit (Technical University of Denmark, DTU) (submittedVersion, other-oa)
  • PMC
Funders
  • Howard Hughes Medical Institute
  • Amgen
  • Bristol-Myers Squibb
  • Eli Lilly and Company
  • Pfizer
  • AstraZeneca
  • Leukemia and Lymphoma Society
  • Melanoma Research Alliance
  • Beth Israel Deaconess Medical Center
  • Celgene
  • Dana-Farber Cancer Institute (R21 CA216772-01A1)
  • Celldex Therapeutics
  • Broad Institute
  • IFM Therapeutics
  • Agios Pharmaceuticals
  • BeiGene
  • Lundbeckfonden (R181-2014-3761)
  • Astellas Pharma
  • Scheme for Promotion of Academic and Research Collaboration
  • National Institutes of Health (CA163205)
  • Genentech (R21 CA216772-01A1)
  • Pharmacyclics
  • National Heart, Lung, and Blood Institute (T32HL007627, R01HL103532)
  • National Cancer Institute (CA-165962, SPORE-2P50CA101942-11A1, R21CA216772, T32CA207021, P50CA101942, CA163205, R50CA211482, 1RO1CA155010-02, R01CA279391, R01CA155010, P50CA165962, P01CA163205)
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
  • Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
Keywords
neoantigen vaccines, glioblastoma, personalized cancer immunotherapy, tumor-infiltrating T cells, CD4+ T cells, CD8+ T cells, T cell receptor repertoire, dexamethasone
MeSH terms
Adult, Aged, Antigens, Neoplasm, Dexamethasone, Glioblastoma, Humans, Middle Aged, Promoter Regions, Genetic, Receptors, Antigen, T-Cell, T-Lymphocytes, DNA Modification Methylases, DNA Methylation, Cancer Vaccines, Tumor Suppressor Proteins, DNA Repair Enzymes, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial. https://app.cochat.ai/papers/10.1038/s41586-018-0792-9
The paper
Keskin, D. B., Anandappa, A. J., Sun, J., Tirosh, I., Mathewson, N. D., Li, S., Oliveira, G., Giobbie-Hurder, A., Felt, K., Gjini, E., Shukla, S. A., Hu, Z., Li, L., Le, P. M., Allesøe, R. L., Richman, A. R., Kowalczyk, M. S., Abdelrahman, S., Geduldig, J. E., . . . Reardon, D. A. (2019). Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial. Nature. https://doi.org/10.1038/s41586-018-0792-9

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.